Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Islets of Langerhans TransplantationDiabetes Mellitus, Type 1Kidney Transplantation
Interventions
DRUG

Belatacept

Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.

Trial Locations (1)

53792

University of Wisconsin, Madison

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Wisconsin, Madison

OTHER